Indications |
Oral Ascariasis Adult: 150 mg as a single dose. Child: 3 mg/kg as a single dose. Oral Mixed ascariasis hookworm infections Adult: 2.5 mg/kg as a single dose, repeated after 7 days in severe cases. Child: 2.5 mg/kg as a single dose, repeated after 7 days in severe cases. Oral Ancylostomiasis Adult: 2.5 mg/kg as a single dose, repeated after 7 days in severe cases. Child: 2.5 mg/kg as a single dose, repeated after 7 days in severe cases. |
Contraindications |
Preexisting blood disorders; pregnancy and lactation; rheumatoid arthritis; severe renal impairment. |
Warnings / Precautions |
Hepatic impairment, Sjogren's syndrome. |
Adverse Reactions |
Nausea, vomiting, diarrhoea, abdominal pain, dizziness and headache. Fever, influenza-like syndrome, arthralgia, muscle pain, rash, taste disturbances and cutaneous vasculitis. Potentially Fatal: Agranulocytosis, leucopenia, thrombocytopenia. |
Drug Interactions |
May increase toxicity of phenytoin. Increases bioavailability of ivermectin; decreases bioavailability of albendazole. Alcohol causes disulfiram-like reaction. See Below for More levamisole Drug Interactions |
Mechanism of Actions |
Levamisole is the active laevo-isomer of tetramisole. It works by paralysing susceptible intestinal worms which are then excreted from the intestines. Levamisole also enhances cellular immune responses in humans. Absorption: Well-absorbed from the GI tract. Peak plasma concentrations are achieved in 1.5-2 hr. Metabolism: Occurs extensively in the liver. Excretion: Mainly in the urine (70% as metabolites and 5% as unchanged drug) and small amounts in the faeces. |
Administration |
Should be taken with food. (Take w/ meals to minimise side effects eg nausea.) |
ATC Classification |
P02CE01 - levamisole ; Belongs to the class of imidazothiazole derivative agents. Used as antinematodal. |
Available As |
|
Levamisole
Post Review about Levamisole Click here to cancel reply.
Levamisole Containing Brands
Levamisole is used in following diseases
Drug - Drug Interactions of Levamisole
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.